Liminal BioSciences, Inc.(NASDAQ : LMNL)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Biotechnology
|VRTX||Vertex Pharmaceuticals, Inc.||0.31%||282.66||1.9%||$481.31m|
|GILD||Gilead Sciences, Inc.||-0.29%||61.63||1.0%||$474.01m|
|REGN||Regeneron Pharmaceuticals, Inc.||-0.37%||588.92||2.6%||$469.90m|
|SNSS||Sunesis Pharmaceuticals, Inc.||-2.58%||3.78||0.7%||$264.24m|
|CRSP||CRISPR Therapeutics AG||2.73%||62.43||0.6%||$164.46m|
|BMRN||BioMarin Pharmaceutical, Inc.||0.45%||83.24||4.2%||$116.70m|
|EXAS||EXACT Sciences Corp.||2.54%||40.39||17.7%||$93.24m|
|IOVA||Iovance Biotherapeutics, Inc.||2.63%||11.33||0.0%||$90.42m|
Liminal BioSciences, Inc. operates as a clinical stage biopharmaceutical company. The firm focuses on developing distinctive novel small molecule therapeutics for inflammatory, fibrotic, and metabolic diseases using drug discovery platform and a data driven approach. The firm has business operations in Canada and the United Kingdom. Its small molecule product candidate, fezagepras, has completed a Phase 1 multi-ascending dose clinical trial and anticipate conducting a comparative Phase 1a single ascending dose clinical trial to provide comparative data to support development plan. The company was founded on October 14, 1994 and is headquartered in Laval, Canada.